Document:

Exhibit
4.17

 

DESCRIPTION
OF SECURITIES

 

The
following description summarizes the material terms and provisions of Verb Technology Company, Inc.’s common stock,
preferred stock and warrants. The following description of our capital stock does not purport to be complete and is subject to,
and qualified in its entirety by, our articles of incorporation, which we refer to as the articles of incorporation, warrants,
and our amended and restated bylaws, as may be amended, which we refer to as the bylaws. The terms of our common stock, preferred
stock and warrants may also be affected by Nevada law.

 

Authorized
Capital Stock

 

Our
authorized capital stock consists of 200,000,000 shares of common stock, $0.0001 par value per share, and 15,000,000 shares of
preferred stock, $0.0001 par value per share, of which 6,000 shares have been designated Series A Convertible Preferred Stock,
or Series A Preferred Stock. As of May 5, 2020, we had 29,894,621 shares of common stock outstanding and 3,246 shares of
Series A Preferred Stock outstanding.

 

Common
Stock

 

All
outstanding shares of our common stock are fully paid and nonassessable. The following summarizes the rights of holders of our
common stock:

 

	 	●	a
    holder of common stock is entitled to one vote per share on all matters to be voted upon generally by the stockholders and
    are not entitled to cumulative voting for the election of directors;
	 	 	 
	 	●	subject
    to preferences that may apply to shares of preferred stock outstanding, the holders of common stock are entitled to receive
    lawful dividends as may be declared by our board of directors;
	 	 	 
	 	●	upon
    our liquidation, dissolution or winding up, the holders of shares of common stock are entitled to receive a pro rata portion
    of all our assets remaining for distribution after satisfaction of all our liabilities and the payment of any liquidation
    preference of any outstanding preferred stock;
	 	 	 
	 	●	there
    are no redemption or sinking fund provisions applicable to our common stock; and
	 	 	 
	 	●	there
    are no preemptive, subscription or conversion rights applicable to our common stock.

 

    	 

     

    

 

Preferred
Stock

 

All
of the preferred stock authorized in our articles of incorporation is undesignated. Our board of directors is authorized, without
further approval from our stockholders, to create one or more series of preferred stock, and to designate the rights, privileges,
preferences, restrictions, and limitations of any given series of preferred stock. Accordingly, our board of directors may, without
stockholder approval, issue shares of preferred stock with dividend, liquidation, conversion, voting, or other rights that could
adversely affect the voting power or other rights of the holders of our common stock. The issuance of preferred stock could have
the effect of restricting dividends payable to holders of our common stock, diluting the voting power of our common stock, impairing
the liquidation rights of our common stock, or delaying or preventing a change in control of us, all without further action by
our stockholders. The following is a summary of the terms and conditions of the Series A Preferred Stock.

 

Series
A Preferred Stock

 

The
rights and preferences of the Series A Preferred Stock are outlined below.

 

Rank
and Liquidation Preference

 

Shares
of Series A Preferred Stock rank prior to our common stock as to distribution of assets upon liquidation events, which include
a liquidation, dissolution or winding up of our company, whether voluntary or involuntary. The liquidation preference of each
share of Series A Preferred Stock is equal to $1,000.00, or the Series A Stated Value, plus any accrued but unpaid dividends on
the Series A Preferred Stock and any other fees or liquidated damages then due and owing under the Certificate of Designation
of Rights, Preferences, and Restrictions of Series A Convertible Preferred Stock, or the Certificate of Designations. If the assets
are insufficient to pay in full such amounts, then the entire assets to be distributed to the holders of our Series A Preferred
Stock shall be distributed pro rata among the holders of our Series A Preferred Stock in accordance with the respective amounts
that would be payable on such shares if all amounts payable thereon were paid in full.

 

Dividend
Rights

 

The
holders of Series A Preferred Stock are entitled to receive lawful dividends as may be declared by our board of directors.

 

Optional
Conversion Rights

 

Each
share of Series A Preferred Stock is convertible at the option of the holder into shares of our common stock at any time. Each
share of Series A Preferred Stock is convertible into the number of shares of common stock as calculated by dividing the Stated
Value of such share of Series A Preferred Stock by the conversion price. The conversion price was initially $1.55 per share of
Series A Preferred Stock, subject to adjustment; therefore, each share of Series A Preferred Stock was initially convertible into
approximately 645 shares of common stock, which number is equal to the quotient of the Stated Value of the Series A Preferred
Stock of $1,000.00 divided by the initial conversion price of $1.55 per share of Series A Preferred Stock. No fractional shares
or scrip representing fractional shares are to be issued upon conversion of the Series A Preferred Stock. As to any fraction of
share that the holder of Series A Preferred Stock would otherwise be entitled to purchase upon conversion, we shall, at our election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the conversion
price, or round up to the next whole share.

 

    	2

     

    

 

The
holders of Series A Preferred Stock cannot convert the Series A Preferred Stock if, after giving effect to the conversion, the
number of shares of our common stock beneficially held by the holder (together with such holder’s affiliates) would be in
excess of 4.99% (or, upon election by a holder prior to the issuance of any shares, 9.99% of the number of shares of our common
stock issued and outstanding immediately after giving effect to the issuance of any shares of common stock issuance upon conversion
of the Series A Preferred Stock held by the holder).

 

We
are also prevented from issuing shares of our common stock upon conversion of the Series A Preferred Stock or exercise of the
August Warrants (as defined below), which, when aggregated with any shares of our common stock issued on or after the issuance
date and prior to such conversion date or exercise date, as applicable (i) in connection with any conversion of the Series A Preferred
Stock issued pursuant to that certain securities purchase agreement entered into on August 14, 2019 by and among us and the investors
thereto, or SPA, (ii) in connection with the exercise of any August Warrants issued pursuant to the SPA, and (iii) in connection
with the exercise of any warrants issued to any registered broker-dealer as a fee in connection with the issuance of the securities
pursuant to the SPA, would exceed 4,459,725 shares of common stock, or 19.99% Cap. This prohibition will terminate upon the approval
by our stockholders of a release from such 19.99% Cap.

 

Mandatory
Conversion Rights

 

In
the event the closing price on The NASDAQ Capital Market is 100% greater than the then-base conversion price on each trading day
for any twenty trading days during a consecutive thirty trading day period, we may, within one trading day after the later of
stockholder approval to issue a number of shares of common stock in excess of the 19.99% Cap and the date that the conversion
shares registration statement filed by us with the Securities and Exchange Commission, or SEC, is declared effective, notify
each holder of Series A Preferred Stock that all or part of such holder’s Series A Preferred Stock, plus all liquidated
damages and other amounts due, were converted into shares of common stock. Any mandatory conversion will be made into the number
of shares of common stock determined on the same basis as the optional conversion rights above.

 

Conversion
Price Adjustments

 

The
conversion price of the Series A Preferred Stock is subject to certain customary adjustments, including upon certain subsequent
equity sales and rights offerings. The conversion price is also subject to downward adjustments if we issue shares of our common
stock or securities convertible into or exercisable for shares of common stock, other than specified excluded securities, at per
share prices less than the then-base conversion price. In this event, the conversion price shall be reduced to then-base conversion
price.

 

    	3

     

    

 

The
conversion price is also subject to adjustment if we issue rights, options, or warrants to holders of common stock entitling them
to subscribe for or purchase shares of common stock at a price per share that is lower than the volume weighted average price
on the date for determination of stockholders entitled to receive such rights, option, or warrants. In this event, the conversion
price shall be multiplied by a fraction of which the denominator is the number of shares of common stock outstanding on the date
of issuance of such rights, options, or warrants plus the number of additional shares of common stock offered for subscription
or purchase, and the numerator shall be the number of shares of common stock outstanding on the date of issuance of such rights,
options, or warrants plus the number of shares that the aggregate offering price of the total number of shares so offered would
purchase at such volume weighted average price.

 

If
we distribute to holders of common stock evidences of our indebtedness or assets, including cash and cash dividends, or rights
or warrants to subscribe for or purchase any security, subject to certain limitations, then the conversion price shall be adjusted
by multiplying the conversion price then in effect immediately prior to the record date fixed for determination of stockholders
entitled to receive such distribution by a fraction of which the denominator shall be the volume weighted average price determined
as of the record date, and of which the numerator shall be the volume weighted average price on such record date less the then
fair market value at such record date of the portion of such assets or evidence of indebtedness or rights or warrants so distributed
applicable to one outstanding share of our common stock as determined by our board of directors in good faith.

 

In
the event of a Fundamental Transaction (as defined below) while the Series A Preferred Stock is outstanding, holders of Series
A Preferred Stock shall have the right to receive, for each share of common stock issuable upon conversion of the shares of our
Series A Preferred Stock that would have been issuable upon such conversion immediately prior to the occurrence of such Fundamental
Transaction, the number of shares of common stock of the successor or acquiring corporation or of us, if we are the surviving
corporation, and any additional consideration receivable as a result of the Fundamental Transaction by a holder of the number
of shares of common stock for which the Series A Preferred Stock is convertible immediately prior to such Fundamental Transaction.
A “Fundamental Transaction” is defined as any time while the Series A Preferred Stock is outstanding (a) we, directly
or indirectly, in one or more related transactions shall effect any merger or consolidation of us with or into another person,
(b) we, directly or indirectly, effect any sale, lease, license, assignment, transfer, conveyance, or other disposition of all
or substantially all of our assets in one or a series of related transactions, (c) any, direct or indirect, purchase offer, tender
offer, or exchange offer (whether by us or another person) is completed pursuant to which holders of our common stock are permitted
to sell, tender, or exchange their shares for other securities, cash, or property and has been accepted by the holders of a majority
of the outstanding common stock, (d) we, directly or indirectly, in one or more related transactions effect any reclassification,
reorganization or recapitalization of our common stock or any compulsory share exchange, pursuant to which the common stock is
effectively converted into or exchanged for other securities, cash or property, or (e) we, directly or indirectly, in one or more
related transactions consummate a stock or share purchase agreement or other business combination (including, without limitation,
a reorganization, recapitalization, spin-off, or scheme of arrangement) with another person, whereby such other person acquires
more than 50% of the outstanding shares of common stock (not including any shares of common stock held by the other person or
other persons making or party to, or associated or affiliated with the other persons making or party to, such stock or share purchase
agreement or other business combination).

 

    	4

     

    

 

Voting
Rights and Protective Provisions

 

The
holders of Series A Preferred Stock have no voting rights. However, we cannot, without the affirmative vote of the holders of
a majority of the then-outstanding shares of Series A Preferred Stock:

 

	 	●	authorize
    or create any class of stock ranking as to dividends, redemption, or distribution of assets upon a liquidation senior to,
    or otherwise pari passu with, the Series A Preferred Stock;
	 	 	 
	 	●	amend
    our articles of incorporation, or other charter documents in any manner that materially and adversely affects any rights of
    the holders;
	 	 	 
	 	●	increase
    the number of authorized shares of Series A Preferred Stock; or
	 	 	 
	 	●	enter
    into any agreement with respect to any of the foregoing.

 

As
long as any shares of Series A Preferred Stock are outstanding, unless the holders of at least 75% in Stated Value of the then-outstanding
shares of Series A Preferred Stock have otherwise given prior written consent, we cannot, directly or indirectly:

 

	 	●	other
    than permitted indebtedness, as long as 25% of the then-outstanding shares of Series A Preferred Stock issued pursuant to
    the SPA are then outstanding, enter into, create, incur, assume, guarantee, or suffer to exist any indebtedness for borrowed
    money of any kind that is or may be senior to the Series A Preferred Stock in dividend rights or liquidation preference, including,
    but not limited to, a guarantee, on or with respect to any of our property or assets now owned or hereafter acquired or any
    interest therein of any income or profits therefrom;
	 	 	 
	 	●	other
    than permitted liens, enter into, create, incur, assume, or suffer to exist any liens of any kind, on or with respect to any
    of our property or assets now owned or hereafter acquired or any interest therein or any income or profits therefrom;
	 	 	 
	 	●	amend
    our charter documents, including, without limitation, our articles of incorporation and bylaws, in any manner that materially
    and adversely affects any rights of the holder;
	 	 	 
	 	●	repay,
    repurchase, or offer to repay, repurchase, or otherwise acquire more than a de minimis number of shares of our common stock,
    common stock equivalents or junior securities, other than as to (a) the conversion shares or warrant shares as permitted under
    the transaction documents and (b) repurchases of common stock or common stock equivalents of departing officers and directors,
    provided that such repurchases shall not exceed an aggregate of $100,000.00 for all officers and directors for so long as
    the Series A Preferred Stock is outstanding;
	 	 	 
	 	●	pay
    cash dividends or distributions on junior securities;
	 	 	 
	 	●	enter
    into any transaction with any affiliate of us that would be required to be disclosed in any public filing with the SEC, unless
    such transaction is made on an arm’s length basis and expressly approved by a majority of the disinterested directors
    of us (even if less than a quorum otherwise required for board approval); or
	 	 	 
	 	●	enter
    into any agreement with respect to the foregoing. 

 

    	5

     

    

 

Reservation
of Shares

 

We
initially were required to reserve 3,245,162 shares of common stock for issuance upon conversion of shares of Series A Preferred
Stock and are required to maintain a sufficient number of reserved shares of common stock to allow for the conversion of all shares
of Series A Preferred Stock.

 

Undesignated
Preferred Stock

 

The
ability to authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting
or other rights or preferences that could impede the success of any attempt to acquire us. These and other provisions may have
the effect of deferring hostile takeovers or delaying changes in control or management of us.

 

Anti-Takeover
Effects of Nevada Law and Our Articles of Incorporation and Bylaws

 

Some
provisions of Nevada law, our articles of incorporation, and our bylaws contain provisions that could make the following transactions
more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise;
or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish
or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including
transactions that provide for payment of a premium over the market price for our shares.

 

These
provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions
are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe
that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited
proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these
proposals could result in an improvement of their terms.

 

    	6

     

    

 

Undesignated
Preferred Stock. The ability of our board of directors, without action by the stockholders, to issue up to 15,000,000 shares
of preferred stock, which was previously authorized but remain undesignated, other than the Series A Preferred Stock, with voting
or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control
of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management
of us.

 

Stockholder
Meetings. Our bylaws provide that a special meeting of stockholders may be called only by our president, by all of
the directors provided that there are no more than three directors, or if more than three, by any three directors, or by the holder
of a majority of our capital stock.

 

Stockholder
Action by Written Consent. Our bylaws allow for any action that may be taken at any annual or special meeting of the stockholders
to be taken without a meeting and without prior notice, if a consent in writing, setting forth the action so taken, is signed
by the holders of outstanding shares having not less than the minimum number of votes that would be necessary to authorize or
take such action at a meeting at which all shares entitled to vote thereon were present and voted.

 

Stockholders
Not Entitled to Cumulative Voting. Our bylaws do not permit stockholders to cumulate their votes in the election of directors.
Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any election of directors
can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock
may be entitled to elect.

 

Nevada
Business Combination Statutes. The “business combination” provisions of Sections 78.411 to 78.444, inclusive,
of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200 stockholders from engaging in
various “combination” transactions with any interested stockholder for a period of two years after the date of the
transaction in which the person became an interested stockholder, unless the transaction is approved by the board of directors
prior to the date the interested stockholder obtained such status or the combination is approved by the board of directors and
thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the
outstanding voting power held by disinterested stockholders, and extends beyond the expiration of the two-year period, unless:

 

	 	●	the
    combination was approved by the board of directors prior to the person becoming an interested stockholder or the transaction
    by which the person first became an interested stockholder was approved by the board of directors before the person became
    an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders;
    or
	 	 	 
	 	●	if
    the consideration to be paid by the interested stockholder is at least equal to the highest of: (a) the highest price per
    share paid by the interested stockholder within the two years immediately preceding the date of the announcement of the combination
    or in the transaction in which it became an interested stockholder, whichever is higher, (b) the market value per share of
    common stock on the date of announcement of the combination and the date the interested stockholder acquired the shares, whichever
    is higher, or (c) for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher.

 

    	7

     

    

 

A
“combination” is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge,
transfer, or other disposition, in one transaction or a series of transactions, with an “interested stockholder” having:
(a) an aggregate market value equal to 5% or more of the aggregate market value of the assets of the corporation, (b) an aggregate
market value equal to 5% or more of the aggregate market value of all outstanding shares of the corporation, (c) 10% or more of
the earning power or net income of the corporation, and (d) certain other transactions with an interested stockholder or an affiliate
or associate of an interested stockholder.

 

In
general, an “interested stockholder” is a person who, together with affiliates and associates, owns (or within two
years, did own) 10% or more of a corporation’s voting stock. The statute could prohibit or delay mergers or other takeover
or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer
our stockholders the opportunity to sell their stock at a price above the prevailing market price.

 

Nevada
Control Share Acquisition Statutes. The “control share” provisions of Sections 78.378 to 78.3793, inclusive, of
the NRS apply to “issuing corporations” that are Nevada corporations with at least 200 stockholders, including at
least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The control
share statute prohibits an acquirer, under certain circumstances, from voting its shares of a target corporation’s stock
after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation’s
disinterested stockholders. The statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less
than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above
thresholds, those shares in an offer or acquisition and acquired within 90 days thereof become “control shares” and
such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions also
provide that if control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all
voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled
to demand payment for the fair value of their shares in accordance with statutory procedures established for dissenters’
rights.

 

A
corporation may elect to not be governed by, or “opt out” of, the control share provisions by making an election in
its articles of incorporation or bylaws, provided that the opt-out election must be in place on the 10th day following the date
an acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds described above. We have
not opted out of the control share statutes, and will be subject to these statutes if we are an “issuing corporation”
as defined in such statutes.

 

The
effect of the Nevada control share statutes is that the acquiring person, and those acting in association with the acquiring person,
will obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or
special meeting. The Nevada control share law, if applicable, could have the effect of discouraging takeovers of us.

 

    	8

     

    

 

Amendment
of Charter Provisions. The amendment of any of the above provisions would require approval by holders of at least a majority
of the total voting power of all of our outstanding voting stock.

 

The
provisions of Nevada law, our articles of incorporation, and our bylaws could have the effect of discouraging others from attempting
hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock
that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes
in the composition of our board of directors and management. It is possible that these provisions could make it more difficult
to accomplish transactions that stockholders may otherwise deem to be in their best interests.

 

Outstanding
Warrants

 

Common Stock Purchase Warrants

 

Exercisability.
The warrants are exercisable immediately upon issuance and at any time for the five-year period from the date of issuance. The
warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us a duly executed exercise
notice accompanied by payment in full for the number of shares of our common stock purchased upon such exercise (except in the
case of a cashless exercise as discussed below).

 

Cashless Exercise.
In the event that a registration statement covering shares of our common stock underlying the warrants is not available for the
resale of such shares of our common stock underlying the warrants, the holder may, in its sole discretion, exercise the warrant
in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment
of the aggregate exercise price, elect instead to receive upon such exercise the net number of shares of our common stock determined
according to the formula set forth in the warrant. In no event will we be required to make any cash payments or net cash settlement
to the registered holder in lieu of issuing shares of our common stock underlying the warrants.

 

Exercise Price.
The initial exercise price per-whole share of our common stock purchasable upon exercise of the warrants is $3.443, or 110% of
the effective offering price. The exercise price is subject to appropriate adjustment in the event of certain stock dividends
and distributions, stock splits stock combinations, reclassifications, or similar events affecting our common stock and also upon
any distribution of assets, including cash, stock, or other property to our stockholders.

 

Transferability.
Subject to applicable laws, the warrants may be transferred at the option of the holders upon surrender of the warrants together
with the appropriate instruments of transfer.

 

Exchange Listing.
The warrants are listed on The NASDAQ Capital Market under the symbol “VERBW.” Trading commenced at the open of the
market on April 5, 2019. We cannot provide assurances that a trading market for the warrants will develop or be maintained.

 

Fundamental Transaction.
If, at any time while the warrants are outstanding, (a) we consolidate or merge with or into another corporation and we are not
the surviving corporation, (b) we sell, lease, license, assign, transfer, convey, or otherwise dispose of all or substantially
all of our assets, (c) any purchase offer, tender offer, or exchange offer (whether by us or another individual or entity) is
completed pursuant to which holders of shares of our common stock are permitted to sell, tender, or exchange their shares of our
common stock for our other securities, cash, or property and has been accepted by the holders of 50% or more of the outstanding
shares of our common stock, (d) we effect any reclassification or recapitalization of shares of our common stock or any compulsory
share exchange pursuant to which the shares of our common stock are converted into or exchanged for other securities, cash, or
property, or (e) we consummate a stock or share purchase agreement or other business combination with another person or entity
whereby such other person or entity acquires more than 50% of the outstanding shares of our common stock, each, a “Common
Stock Purchase Warrant Fundamental Transaction,” then upon any subsequent exercise of the warrants, the holders thereof
will have the right to receive the same amount and kind of securities, cash, or property as it would have been entitled to receive
upon the occurrence of such Common Stock Purchase Warrant Fundamental Transaction if it had been immediately prior to such Common
Stock Purchase Warrant Fundamental Transaction, the holder of the number of warrant shares then issuable upon exercise of the
warrant, and any additional consideration payable as part of the Common Stock Purchase Warrant Fundamental Transaction.

 

Rights as a Stockholder.
Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of our common stock, the
holder of the warrant does not have the rights or privileges of a holder of our common stock, including any voting rights, until
the holder exercises the warrant.

 

August
2019 Warrants

 

On
August 14, 2019, we entered into the SPA with certain purchasers named therein, or the Preferred Purchasers, pursuant to which
we agreed to issue and sell to the Preferred Purchasers, in addition to shares of our Series A Preferred Stock, warrants, which
we refer to as the August Warrants, to purchase up to approximately 3.87 million shares of our common stock. We closed the offering
on August 14, 2019 and issued 5,030 shares of Series A Preferred Stock and granted the August Warrants exercisable for up to 3,245,162
shares of common stock in connection therewith. We received gross proceeds equal to $5,030,000.

 

Exercisability.
The warrants are exercisable from and after six months after the date of issuance and at any time for the five-year period from
the date of issuance. The warrants will be exercisable, at the option of each holder, in whole or in part, by delivering to us
a duly executed exercise notice accompanied by payment in full for the number of shares of our common stock purchased upon such
exercise (except in the case of a cashless exercise as discussed below).

 

Cashless
Exercise. In the event that a registration statement covering shares of our common stock underlying the warrants is not available
for the resale of such shares of our common stock underlying the warrants, the holder may, in its sole discretion, exercise the
warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise
in payment of the aggregate exercise price, elect instead to receive upon such exercise the net number of shares of our common
stock determined according to the formula set forth in the warrant. In no event will we be required to make any cash payments
or net cash settlement to the registered holder in lieu of issuing shares of our common stock underlying the warrants.

 

Exercise
Price. The initial exercise price per-whole share of our common stock purchasable upon exercise of the warrants was $1.88.
The exercise price is subject to appropriate adjustment in the event of certain stock dividends and distributions, stock splits,
stock combinations, reclassifications, or similar events affecting our common stock and also upon any distribution of assets,
including cash, stock, or other property to our stockholders. If we or any subsidiary, at any time while the August Warrants
are outstanding, sell or grant any option to purchase, or sell or grant any right to reprice or otherwise dispose of or issue
any common stock or common stock equivalents at an effective price less than the exercise price then in effect, then the exercise
price shall be reduced to the lower exercise price then in effect, subject to adjustment for reverse and forward stock splits,
recapitalizations, and similar transactions and subject to certain exceptions. If we, at any time while the August Warrants are
outstanding, issue rights, options, or warrants to all holders of common stock entitling them to subscribe for or purchase shares
of common stock at a price per share less than the volume weighted average price on the record date mentioned below, then the
exercise price shall be multiplied by a fraction, of which the denominator shall be the number of shares of common stock outstanding
on the date of issuance of such rights, options, or warrants plus the number of additional shares of common stock offered for
subscription or purchase, and of which the numerator shall be the number of shares of common stock outstanding on the date of
issuance of such rights, options, or warrants plus the number of shares that the aggregate offering price of the total number
of shares so offered (assuming receipt by us in full of all consideration payable upon exercise of such rights, options or warrants)
would purchase at such volume weighted average price. Such adjustment shall be made whenever such rights, options, or warrants
are issued, and shall become effective immediately after the record date for the determination of stockholders entitled to receive
such rights, options, or warrants.

 

    	9

     

    

 

Transferability.
Subject to applicable laws, the warrants may be transferred at the option of the holders upon surrender of the warrants together
with the appropriate instruments of transfer.

 

Exchange
Listing. Our August Warrants are not listed on any securities exchange or other trading system and we do not intend to apply for
listing on any securities exchange or other trading system.

 

Fundamental
Transaction. If, at any time while the warrants are outstanding, (a) we consolidate or merge with or into another corporation
and we are not the surviving corporation, (b) we sell, lease, license, assign, transfer, convey, or otherwise dispose of all or
substantially all of our assets, (c) any purchase offer, tender offer, or exchange offer (whether by us or another individual
or entity) is completed pursuant to which holders of shares of our common stock are permitted to sell, tender, or exchange their
shares of our common stock for our other securities, cash, or property and has been accepted by the holders of 50% or more of
the outstanding shares of our common stock, (d) we effect any reclassification or recapitalization of shares of our common stock
or any compulsory share exchange pursuant to which the shares of our common stock are converted into or exchanged for other securities,
cash, or property, or (e) we consummate a stock or share purchase agreement or other business combination with another person
or entity whereby such other person or entity acquires more than 50% of the outstanding shares of our common stock, each, an “August
Warrant Fundamental Transaction,” then upon any subsequent exercise of the warrants, the holders thereof will have the right
to receive the same amount and kind of securities, cash, or property as it would have been entitled to receive upon the occurrence
of such August Warrant Fundamental Transaction if it had been immediately prior to such August Warrant Fundamental Transaction,
the holder of the number of warrant shares then issuable upon exercise of the warrant, and any additional consideration payable
as part of the August Warrant Fundamental Transaction.

 

Rights
as a Stockholder. Except as otherwise provided in the warrants or by virtue of such holder’s ownership of shares of
our common stock, the holder of the warrant does not have the rights or privileges of a holder of our common stock, including
any voting rights, until the holder exercises the warrant.

 

February
2020 Warrants

 

In connection with our
private placement of common stock in February 2020, the Preferred Purchasers who, as of February 7, 2020, continued to
own shares of our Series A Preferred Stock (a) waived their respective rights, or the February 2020 Waiver, to participate in
our private placement, and (b) declined to accept the price protection rights to which they otherwise were entitled as
holders of shares of our Series A Preferred Stock. In connection with the February 2020 Waiver, we granted to each of our Preferred
Purchasers who continued to own shares of our Series A Preferred Stock as of February 7, 2020 a five-year common stock purchase
warrant, or February 2020 Warrants, the terms of which are substantially similar to the terms of our August Warrants, with the
sole material differences being the grant date and the $1.55 per-share exercise price. The initial per-share exercise price of
our August Warrants was $1.88 and, by virtue of our private placement, the per-share exercise price was modified
to $1.20. Our February 2020 Warrants are not listed on any securities exchange or other trading system and we do not intend
to apply for listing on any securities exchange or other trading system.

 

    	10

     

    

 

As
of May 5, 2020, we had 13,651,051 shares of our common stock underlying outstanding warrants, having a weighted-average exercise
price of approximately $2.72 per share.

 

Outstanding
Options and Awards

 

As
of May 5, 2020, we had 4,532,608 shares of our common stock underlying outstanding stock options, having a weighted-average
exercise price of approximately $1.72 per share, and 2,341,305 restricted stock awards having a weighted-average grant date fair
value of 1.40 issued under our 2019 Omnibus Incentive Plan, respectively.

 

Choice
of Forum

 

Our
bylaws provide that, unless we consent in writing to the selection of an alternative forum, the courts in the State of Nevada
shall be the exclusive forum for any litigation relating to our internal affairs, including, without limitation: (a) any derivative
action brought on behalf of us, (b) any action asserting a claim for breach of fiduciary duty to us or our stockholders by any
current or former officer, director, employee, or agent of us, or (c) any action against us or any current or former officer,
director, employee, or agent of us arising pursuant to any provision of the NRS, the articles of incorporation, or the bylaws.

 

Transfer
Agent and Registrar 

 

Our
transfer agent and registrar for our common stock is VStock Transfer, LLC, 18 Lafayette Place, Woodmere, New York 11598. Its telephone
number is 855-9VSTOCK.

 

Listing

 

Shares
of our common stock are being traded on The NASDAQ Capital Market under the symbol “VERB.” Our common stock purchase
warrants are being traded on The NASDAQ Capital Market under the symbol “VERBW.”

 

    	11Exhibit
10.43

 

VERB
TECHNOLOGY COMPANY, INC.

 

INDEMNIFICATION
AGREEMENT

 

This
Indemnification Agreement (this “Agreement”) is made and entered into as of the ____ day of December, 2019, by and
between Verb Technology Company, Inc., a Nevada corporation (the “Corporation”), and _________________ (“Indemnitee”).

 

WITNESSETH:

 

WHEREAS,
Indemnitee is currently serving or is about to begin serving as a director and/or Officer (as hereinafter defined) of the
Corporation, and Indemnitee is willing, subject to, among other things, the Corporation’s execution and performance of this
Agreement, to continue in or assume such capacity or capacities;

 

WHEREAS,
the Amended and Restated Bylaws of the Corporation provide that the Corporation shall indemnify and advance expenses to all
directors and Officers of the Corporation in the manner set forth therein and to the fullest extent permitted by applicable law,
and to such greater extent as applicable law may thereafter permit, and the Corporation’s Articles of Incorporation, as
amended, provide for the limitation of liability for directors and Officers and the right to indemnification to the fullest extent
permitted by applicable law; and

 

WHEREAS,
in order to induce Indemnitee to provide services as contemplated hereby, the Corporation has deemed it to be in its best
interest to enter into this Agreement with Indemnitee;

 

NOW,
THEREFORE, in consideration of Indemnitee’s agreement to provide services to the Corporation and/or certain of its affiliates
as contemplated hereby, the mutual agreements contained herein, and other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereto stipulate and agree as follows:

 

ARTICLE
I

Definitions

 

Section
1.1. As used herein, the following words and terms shall have the following respective meanings (whether singular or plural):

 

“Articles
of Incorporation” means the Articles of Incorporation of the Corporation (as they may be amended or restated from time
to time).

 

“Board
of Directors” means the board of directors of the Corporation.

 

“Bylaws”
means the Amended and Restated Bylaws of the Corporation (as they may be amended or restated from time to time).

 

    	 

     

    

 

“Change
of Control” means:

 

	 	(i)	The acquisition
    by any individual, entity, or group (within the meaning of Sections 13(d)(3) or 14(d)(2) of the Exchange Act) (a “Person”)
    of beneficial ownership (within the meaning of Rule 13d-3 promulgated under the Exchange Act) of 20% or more of either (1)
    the then-outstanding shares of common stock of the Corporation (the “Outstanding Corporation Common Stock”)
    or (2) the combined voting power of the then-outstanding voting securities of the Corporation entitled to vote generally in
    the election of directors (the “Outstanding Corporation Voting Securities”); provided, however,
    that, for purposes of this subsection (i), the following acquisitions shall not constitute a Change of Control: (A) any acquisition
    directly from the Corporation, (B) any acquisition by the Corporation, (C) any acquisition by any employee benefit plan (or
    related trust) sponsored or maintained by the Corporation or any entity controlled by the Corporation, or (D) any acquisition
    by any entity pursuant to a transaction that complies with clauses (1), (2), and (3) of subsection (iii) of this definition;
    or
	 	 	 
	 	(ii)	Individuals who,
    as of the date hereof, constitute the Board of Directors (the “Incumbent Board”), cease for any
    reason to constitute at least a majority of the Board of Directors; provided, however, that any individual becoming
    a director subsequent to the date hereof, whose election, or nomination for election by the Corporation’s stockholders
    was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as
    though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial
    assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal
    of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the
    Board of Directors; or 
	 	 	 
	 	(iii)	Consummation of
    a reorganization, merger, or consolidation or sale or other disposition of all or substantially all of the assets of the Corporation
    (a “Business Combination”), in each case, unless, following such Business Combination, (1) all or
    substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Corporation
    Common Stock and Outstanding Corporation Voting Securities immediately prior to such Business Combination beneficially own,
    directly or indirectly, more than 50% of, respectively, the then-outstanding shares of common stock and the combined voting
    power of the then-outstanding voting securities entitled to vote generally in the election of directors, as the case may be,
    of the entity resulting from such Business Combination (including, without limitation, an entity that as a result of such
    transaction owns the Corporation or all or substantially all of the Corporation’s assets either directly or through
    one or more subsidiaries) in substantially the same proportions as their ownership, immediately prior to such Business Combination,
    of the Outstanding Corporation Common Stock and Outstanding Corporation Voting Securities, as the case may be, (2) no Person
    (excluding any entity resulting from such Business Combination or any employee benefit plan (or related trust) of the Corporation
    or such entity resulting from such Business Combination) beneficially owns, directly or indirectly, 20% or more of, respectively,
    the then-outstanding shares of common equity of the entity resulting from such Business Combination or the combined voting
    power of the then-outstanding voting securities of such entity except to the extent that such ownership existed prior to the
    Business Combination, and (3) at least a majority of the members of the board of directors of the corporation, or the similar
    managing body of a non-corporate entity, resulting from such Business Combination were members of the Incumbent Board at the
    time of the execution of the initial agreement, or of the action of the Board of Directors, providing for such Business Combination;
    or 
	 	 	 
	 	(iv)	Approval by the
    stockholders of the Corporation of a complete liquidation or dissolution of the Corporation; or 
	 	 	 
	 	(v)	A change of control
    as defined in any employment agreement, change of control agreement, or other agreement between the Corporation and Indemnitee.
    

 

“Covered
Capacity” means, with respect to any person, that such person (or a person for whom he or she is serving as a legal
representative) is or was a director, officer, employee, or agent of the Corporation, or is or was serving at the request of the
Corporation as director, manager, officer, trustee, general partner, member, fiduciary, employee, or agent of any other enterprise,
in each case (i) whether or not such person was serving in that capacity at the time any liability or expense is incurred and
(ii) whether the basis for any Proceeding brought against such person is alleged action in an official capacity as a director,
manager, officer, trustee, general partner, member, fiduciary, employee, or agent or any other capacity while serving as a director,
manager, officer, trustee, general partner, member, fiduciary, employee, or agent.

 

    	 

     

    

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

“Expenses”
include all direct and indirect costs, fees, and expenses of any type or nature, including, without limitation, all attorneys’
fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, fees of private investigators
and professional advisors, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, fax
transmission charges, secretarial services, and all other disbursements or expenses in connection with prosecuting, defending,
preparing to prosecute or defend, investigating, being or preparing to be a witness in, settlement or appeal of, or otherwise
participating in a Proceeding, including reasonable compensation for time spent by Indemnitee for which he or she is not otherwise
compensated by the Corporation or any third party. “Expenses” also include expenses incurred in connection with any
appeal resulting from any Proceeding, including the premium for, security for, and other costs relating to, any cost bond, supersedeas
bond, or other appeal bond or its equivalent. “Expenses” do not include amounts paid in settlement by Indemnitee or
the amount of judgments or fines against Indemnitee.

 

“Independent
Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither
presently is, nor in the five (5) years has been, retained to represent: (i) the Corporation or Indemnitee in any matter material
to either such party or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. The term
“Independent Counsel” does not include any person who, under the applicable standards of professional conduct then
prevailing, would have a conflict of interest in representing either the Corporation or Indemnitee in an action to determine Indemnitee’s
rights under this Agreement, the Articles of Incorporation, the Bylaws of the Corporation, or under any agreement between Indemnitee
and the Corporation.

 

“NRS”
means the Nevada Revised Statutes (as amended from time to time).

 

“Officer”
means the President, the Treasurer, the Secretary, the Chief Executive Officer, the Chief Financial Officer, and each Vice President
of the Corporation and any other corporation, partnership, limited liability company, association, joint venture, trust, employee
benefit plan, or other enterprise for which such person is or was serving in such position at the request of the Corporation (and
all variants of the preceding positions such as assistant treasurer, assistant secretary, senior vice president, and similar modifications),
in each case elected or appointed pursuant to proper corporate authority, and each other person designated by the President of
the Corporation from time to time as constituting an “Officer.”

 

“Proceeding”
includes a threatened, pending, or completed action, suit, arbitration, alternate dispute resolution, investigation, inquiry,
administrative hearing, appeal, or any other actual, threatened, or completed proceedings with or brought in the right of the
Corporation or otherwise and whether civil, criminal, administrative, or investigative in nature.

 

ARTICLE
II

Services
by Indemnitee

 

Section
2.1. Indemnitee agrees to serve, or continue to serve, in his or her current capacity or capacities as a director, Officer,
employee, agent, or fiduciary of the Corporation, as applicable. Indemnitee may also serve, as the Corporation may reasonably
request from time to time, as a director, Officer, employee, agent, or fiduciary of any other corporation, partnership, limited
liability company, association, joint venture, trust, employee benefit plan, or other enterprise in which the Corporation has
an interest. Indemnitee and the Corporation each acknowledge that they have entered into this Agreement as a means of inducing
Indemnitee to serve or to continue to serve the Corporation in such capacities. Indemnitee may at any time and for any reason
resign from such position or positions (subject to any other contractual obligation or any obligation imposed by operation of
law). The Corporation shall have no obligation under this Agreement to continue Indemnitee in any such position for any period
of time and shall not be precluded by the provisions of this Agreement from removing Indemnitee from any such position at any
time.

 

    	 

     

    

 

ARTICLE
III

Third-Party
Proceedings

 

Section
3.1. The Corporation shall indemnify Indemnitee if he or she was or is a party or is threatened to be made a party to any
Proceeding, except an action by or in the right of the Corporation, by reason of the fact that he or she is or was serving or
acting in a Covered Capacity, against Expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred
by Indemnitee in connection with the Proceeding if he or she: (a) is not liable pursuant to NRS Section 78.138 or (b) acted in
good faith and in a manner that Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation,
and, with respect to any criminal action or Proceeding, had no reasonable cause to believe his or her conduct was unlawful. The
termination of any Proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent,
does not, of itself, create a presumption that Indemnitee is liable pursuant to NRS Section 78.138 or did not act in good faith
and in a manner that Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation or that,
with respect to any criminal action or proceeding, he or she had reasonable cause to believe that his or her conduct was unlawful.

 

ARTICLE
IV

Derivative
Actions

 

Section
4.1. The Corporation shall indemnify Indemnitee if he or she was or is a party or is threatened to be made a party to any
threatened, pending, or completed action or suit by or in the right of the Corporation to procure a judgment in its favor, by
reason of the fact that Indemnitee is or was serving or acting in a Covered Capacity, against Expenses and amounts paid in settlement
thereof if Indemnitee: (a) is not liable pursuant to NRS Section 78.138 or (b) acted in good faith and in a manner that he or
she reasonably believed to be in or not opposed to the best interests of the Corporation. Indemnification may not be made for
any claim, issue, or matter as to which Indemnitee has been adjudged by a court of competent jurisdiction, after exhaustion of
all appeals therefrom, to be liable to the Corporation or for amounts paid in settlement to the Corporation, unless and only to
the extent that the court in which the action or suit was brought or other court of competent jurisdiction determines upon application
that, in view of all the circumstances of the case, the person is fairly and reasonably entitled to indemnity for such Expenses
as the court deems proper.

 

ARTICLE
V

Party
Who is Wholly or Partially Successful

 

Section
5.1. Notwithstanding any other provisions of this Agreement, to the extent that Indemnitee is a party to or a participant
in and is successful on the merits or otherwise in any Proceeding or in defense of any claim, issue, or matter in any Proceeding,
in whole or in part, to which Indemnitee was or is a party or is otherwise involved by reason of the fact that he or she is or
was serving or acting in a Covered Capacity, the Corporation shall indemnify and hold harmless Indemnitee against all Expenses
actually and reasonably incurred by Indemnitee in connection with any Proceeding or defense. If Indemnitee is not wholly successful
in the Proceeding, the Corporation shall indemnify and hold harmless Indemnitee against all Expenses actually and reasonably incurred
by him or her or on his or her behalf in connection with each claim, issue, or matter on which Indemnitee was successful. The
termination of any claim, issue, or matter in the Proceeding by dismissal, with or without prejudice, by reason of settlement,
judgment, order, or otherwise, shall be deemed to be a successful result as to such Proceeding, claim, issue, or matter, so long
as there has been no finding that Indemnitee (i) is liable pursuant to NRS Section 78.138 or (ii) did not act in good faith and
in a manner that Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect
to any criminal proceeding or action, had no reasonable cause to believe his or her conduct was unlawful.

 

ARTICLE
VI

Expenses
as Witness

 

Section
6.1. To the extent Indemnitee is, by reason of his or her serving or acting in a Covered Capacity, a witness in any Proceeding
to which Indemnitee is not a party, Indemnitee shall be indemnified and held harmless against all Expenses actually and reasonably
incurred by him or her or on his or her behalf in connection with the Proceeding and his or her acting as a witness in it.

 

    	 

     

    

 

ARTICLE
VII

Exclusions

 

Section
7.1. Notwithstanding any provision in this Agreement, the Corporation is not obligated under this Agreement to make any indemnification
payments in connection with any claim made against Indemnitee:

 

	 	(a)	For which payment
    has actually been received by or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with
    respect to any excess beyond the amount actually received under any insurance policy, contract, agreement, or other indemnity
    provision or otherwise; 
	 	 	 
	 	(b)	For an accounting
    of profits made from the purchase and sale, or sale and purchase, by Indemnitee of securities of the Corporation within the
    meaning of Section 16(b) of the Exchange Act; or 
	 	 	 
	 	(c)	Except as provided
    for in Sections 8.1 or 12.3 of this Agreement, in connection with any Proceeding or any part of any Proceeding, initiated
    by Indemnitee, including those initiated against the Corporation or its officers, directors, or employees, unless (i) the
    Board of Directors authorizes the Proceeding or part thereof before its initiation or (ii) the Corporation provides the indemnification
    in its sole discretion, pursuant to the powers vested in the Corporation under applicable law.

 

ARTICLE
VIII

Advancement
of Expenses

 

Section
8.1. Notwithstanding any other provision of this Agreement and to the fullest permitted by applicable law, the Corporation
shall advance the Expenses incurred by Indemnitee, or reasonably expected by Indemnitee to be incurred by him or her within three
months, in connection with any Proceeding to which Indemnitee was or is a party or is otherwise involved by reason of the fact
that he or she is or was serving or acting in a Covered Capacity, as soon as practicable but in any event not more than ten (10)
days after receipt by the Corporation of a statement requesting the advances, whether the statement is submitted before or after
final disposition of any Proceeding. Unless otherwise required by law, the Corporation shall not require that Indemnitee provide
any form of security for repayment of or charge any interest on any amounts advanced pursuant to this Section 8.1. The advances
shall be made without regard to Indemnitee’s ability to repay the Expenses and without regard to any belief or determination
as to Indemnitee’s ultimate entitlement to be indemnified. Advances shall include any and all reasonable Expenses incurred
in pursuing a Proceeding to enforce the right of advancement, including Expenses incurred in preparing statements to the Corporation
to support the advances claimed. Indemnitee qualifies for advances, to the fullest extent permitted by applicable law, solely
upon the execution and delivery to the Corporation of an undertaking providing that Indemnitee undertakes to repay the advance
to the extent it is ultimately determined that Indemnitee is not entitled to be indemnified by the Corporation under the provisions
of this Agreement, the Articles of Incorporation, Bylaws of the Corporation, or an agreement between the Corporation and Indemnitee.
This section does not apply to any claim made by Indemnitee for any indemnification payment that is excluded pursuant to Section
7.1 of this Agreement.

 

ARTICLE
IX

Notices

 

Section
9.1. Indemnitee agrees to notify the Corporation in writing promptly after being served with any summons, citation, subpoena,
complaint, indictment, inquiry, information request, or other document relating to any Proceeding or matter that may be subject
to indemnification, hold harmless, or exoneration rights or the advancement of expenses; provided, however, that
the failure of Indemnitee so to notify the Corporation shall not relieve the Corporation of any obligation it may have to Indemnitee
under this Agreement or otherwise. Indemnitee may deliver to the Corporation a written application to indemnify and hold harmless
Indemnitee in accordance with this Agreement. The application may be delivered from time to time and may be amended and supplemented
and at such times as Indemnitee deems appropriate in his or her sole discretion. After a written application for indemnification
is delivered by Indemnitee, Indemnitee’s entitlement to indemnification shall be determined pursuant to Articles X, XI,
and XII of this Agreement.

 

    	 

     

    

 

ARTICLE
X

Procedures

 

Section
10.1. To the fullest extent permitted by law, the indemnification provided for in this Agreement shall be deemed mandatory.
To the extent that, under applicable law, any indemnification provided for in this Agreement is treated as discretionary, any
indemnification determination, unless ordered by a court or advanced pursuant to Section 8.1 of this Agreement, may be made by
the Corporation only as authorized in the specific case upon a determination that the indemnification of Indemnitee is proper
in the circumstances. Such determination must be made:

 

	 	(a)	by the stockholders
    of the Corporation; 
	 	 	 
	 	(b)	by the Board of
    Directors by a majority vote of a quorum consisting of directors who are not parties to the Proceeding;
	 	 	 
	 	(c)	if a majority vote
    of a quorum of directors who are not parties to the Proceeding so orders, by Independent Counsel in a written opinion; or
	 	 	 
	 	(d)	if a quorum consisting
    of directors who are not parties to the Proceeding cannot be obtained, by Independent Counsel in a written opinion. 

 

Notwithstanding
the foregoing, if at any time during the two (2)-year period prior to the date of any written application for indemnification
submitted by Indemnitee in connection with a particular Proceeding there shall have occurred a Change of Control, the Board of
Directors shall direct (unless Indemnitee otherwise agrees in writing) that the indemnification determination shall be made by
Independent Counsel in a written opinion.

 

Section
10.2. If the determination of Indemnitee’s entitlement to indemnification is to be made by Independent Counsel, the
Independent Counsel must be selected as provided in this Section 10.2. The Independent Counsel shall be selected by Indemnitee
and Indemnitee must give written notice to the Corporation advising it of the Independent Counsel’s identity so selected,
unless Indemnitee requests in writing that the Independent Counsel be selected by the Board of Directors. If the Independent Counsel
is selected by the Board of Directors, the Corporation must give written notice to Indemnitee setting forth the identity of the
Independent Counsel. In either event, Indemnitee or the Corporation, as the case may be, may, within ten (10) days after the written
notice of selection is received, deliver to the other party a written objection to the selection. The objection may be asserted
only on the grounds that the Independent Counsel selected does not meet the requirements of an “Independent Counsel”
as defined in Article I of this Agreement, and the objection must set forth with particularity the factual basis of the assertion.
Absent a proper and timely objection, the person so selected shall act as Independent Counsel. If within twenty (20) days after
submission by Indemnitee of a request for indemnification, no Independent Counsel has been selected, either the Corporation or
Indemnitee may petition a court with jurisdiction over the parties for resolution of the objection and/or the appointment of a
person to be Independent Counsel selected by the court.

 

Section
10.3. The Corporation agrees to pay the reasonable fees and Expenses of Independent Counsel and to indemnify fully
and hold the Independent Counsel harmless against any and all Expenses, claims, liabilities, and damages arising out of or relating
to this Agreement or the Independent Counsel’s engagement.

 

Section
10.4. The Corporation must promptly advise Indemnitee in writing if a determination is made that Indemnitee is not entitled
to indemnification and must include a description of the reasons or basis for denial. If it is determined Indemnitee is entitled
to indemnification, the payment to Indemnitee must be made as soon as practicable but in no event more than ten (10) days after
the determination. Indemnitee must reasonably cooperate with the persons making the determination and, upon request, must provide
such persons with documents and information (that are not privileged or otherwise protected) reasonably available to Indemnitee
and reasonably necessary to the determination. All Expenses incurred by Indemnitee in cooperating with the persons making the
determination shall be paid by the Corporation (irrespective of the determination as to indemnification) and the Corporation hereby
indemnifies and agrees to hold Indemnitee harmless from those Expenses.

 

    	 

     

    

 

ARTICLE
XI

Presumptions

 

Section
11.1. In determining whether Indemnitee is entitled to indemnification under this Agreement, the person or persons making
the determination must presume that Indemnitee is entitled to indemnification under this Agreement and the Corporation has the
burden of proof to overcome that presumption. Moreover, if at any time during the two (2)-year period prior to the date of any
written application for indemnification submitted by Indemnitee in connection with a particular Proceeding or other matter there
shall have occurred a Change of Control, the foregoing presumption may only be overcome by clear and convincing evidence. Neither
of the following is a defense to an action seeking a determination granting indemnity to Indemnitee or creates a presumption that
Indemnitee has not met the applicable standard of conduct: (i) the failure of the Corporation (including its directors or Independent
Counsel) to have made a determination before the beginning of an action seeking a ruling that indemnification is proper nor (ii)
an actual determination by the Corporation (including its directors or Independent Counsel) that Indemnitee has not met the applicable
standard of conduct.

 

Section
11.2. If the persons or entity selected under Article X of this Agreement to determine whether Indemnitee is entitled to indemnification
have not made a determination within thirty (30) days after receipt by the Corporation of the request for it, the requisite determination
of entitlement to indemnification shall be deemed to have been made and Indemnitee is entitled to such indemnification, absent
(i) a misstatement by Indemnitee of a material fact or an omission of material fact necessary to make his or her statements not
materially misleading made in connection with the request for indemnification (which misstatement or omission is shown by the
Corporation to be of sufficient importance that it would likely alter the applicable determination) or (ii) a final judicial determination
that indemnification is expressly prohibited under applicable law. The 30-day period may be extended for a reasonable time, not
to exceed fifteen (15) additional days, if the persons or entity making the determination requires the additional time for obtaining
or evaluating documents or information.

 

Section
11.3. The termination of any Proceeding or any claim therein, by judgment, order, settlement, or conviction, or upon a plea
of nolo contendere does not (except as expressly provided elsewhere in this Agreement) of itself adversely affect the right of
Indemnitee to indemnification or create a presumption that Indemnitee did not meet any particular standard of conduct, did not
act in good faith and in a manner that Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation
or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe his or her conduct was unlawful.

 

Section
11.4. In determining good faith, Indemnitee must be deemed to have acted in good faith and in a manner that he or she reasonably
believed to be in or not opposed to the best interests of the Corporation if Indemnitee’s action is based on the records
or books of account of the Corporation, including financial statements, or on information, opinions, reports, or statements supplied
to Indemnitee by the directors or officers of the Corporation or other enterprise in the course of their duties, or on the advice
of legal counsel for the Corporation or the enterprise or on information or records given or reports made by an independent certified
public accountant or by an appraiser or other expert.

 

Section
11.5. The knowledge and actions or failures to act of any other director, officer, trustee, partner, member, fiduciary, agent,
or employee of the Corporation or other enterprise shall not be imputed to Indemnitee for the purposes of determining his or her
right to indemnification.

 

ARTICLE
XII

Remedies of Indemnitee

 

Section
12.1. If a determination is made that Indemnitee is not entitled to indemnification under this Agreement, any judicial Proceeding
or arbitration begun pursuant to this Agreement must be conducted in all respects as a de novo trial or arbitration on the merits
and Indemnitee shall not be prejudiced by reason of the adverse determination. In such a Proceeding or arbitration, Indemnitee
is presumed to be entitled to indemnification and the Corporation has the burden of proving Indemnitee is not entitled to be indemnified.
Moreover, if at any time during the two (2)-year period prior to the date of any written application for indemnification submitted
by Indemnitee in connection with a particular Proceeding or other matter there shall have occurred a Change of Control, the Corporation
will be deemed to have satisfied such burden only if it meets the standard of proof by clear and convincing evidence. The Corporation
may not refer to or introduce into evidence any determination made pursuant to Section 11.1 of this Agreement adverse to Indemnitee
for any purpose. If Indemnitee begins a judicial Proceeding or arbitration seeking indemnification, Indemnitee is not required
to reimburse the Corporation for any advances pursuant to Section 8.1 of this Agreement until a final determination is made with
respect to Indemnitee’s right to indemnification, after all rights of appeal have been exhausted or lapsed.

 

    	 

     

    

 

Section
12.2. If it has been determined that Indemnitee is entitled to indemnification, the Corporation is bound by that determination
in any judicial Proceeding or arbitration commenced by Indemnitee seeking to compel the indemnification, absent (i) a misstatement
by Indemnitee of a material fact or an omission of a material fact necessary to make Indemnitee’s statement not materially
misleading connected with the request for indemnification (which misstatement or omission is shown by the Corporation to be of
sufficient importance that it would likely alter the applicable determination) or (ii) a prohibition of the indemnification under
applicable law. In any Proceeding or arbitration commenced by Indemnitee seeking indemnification, the Corporation is precluded
from asserting that the procedures and presumptions of this Agreement are not valid, binding, and enforceable and must stipulate
that the Corporation is bound by all the provisions of this Agreement.

 

Section
12.3. The Corporation shall indemnify and hold harmless Indemnitee to the fullest extent permitted by applicable law against
all Expenses and, upon Indemnitee’s request, shall advance to Indemnitee, within ten (10) days after the Corporation’s
receipt of a request, Indemnitee’s Expenses incurred in connection with any judicial Proceeding or arbitration brought by
Indemnitee to enforce his or her right for indemnification or to recover advances under any insurance policy maintained for the
benefit of Indemnitee, regardless of whether Indemnitee is ultimately determined to be entitled to such indemnification, advance,
or insurance recovery.

 

ARTICLE
XIII

Contribution;
Joint Liability

 

Section
13.1. To the fullest extent permissible under applicable law, if the indemnification rights provided for in this Agreement
are unavailable to Indemnitee in whole or in part for any reason whatsoever (other than by reason of the language of any express
exclusion contained in this Agreement), the Corporation, instead of indemnifying and holding Indemnitee harmless, shall contribute
to the payment thereof, in the first instance, by paying the entire amount incurred by Indemnitee, whether for judgments, liabilities,
fines, penalties, amounts paid or to be paid in settlement, and/or for Expenses, in connection with any Proceeding without requiring
Indemnitee to contribute to the payment, and the Corporation hereby waives and relinquishes any right of contribution it may have
at any time against Indemnitee. The Corporation shall not enter into any settlement of any Proceeding in which the Corporation
is jointly liable with Indemnitee, or would be joined in the Proceeding, unless the settlement provides for a full and final release
of all claims asserted against Indemnitee. The Corporation hereby agrees to indemnify fully and hold harmless Indemnitee from
any claims for contribution that may be brought by officers, directors, or employees of the Corporation other than Indemnitee
who may be jointly liable with Indemnitee.

 

ARTICLE
XIV

Subrogation

 

Section
14.1. If any payment is made under this Agreement, the Corporation is subrogated to the extent of such payment to all the
rights of recovery of Indemnitee, who must within a reasonable period of time after payment execute all papers required and take
all action necessary to secure those rights, including the execution of such documents as are necessary to enable the Corporation
to bring suit to enforce those rights.

 

ARTICLE
XV

Severability

 

Section
15.1. If any provision or provisions of this Agreement shall be held to be invalid, illegal, or unenforceable for any reason
whatsoever: (a) the validity, legality, and enforceability of the remaining provisions of this Agreement (including, but not limited
to, each portion of any paragraph containing any such provision held to be invalid, illegal, or unenforceable, that is not itself
held to be invalid, illegal, or unenforceable) shall not in any way be affected or impaired thereby and (b) to the fullest extent
possible, the provisions of this Agreement (including, but not limited to, each such portion of any paragraph containing any such
provision held to be invalid, illegal, or unenforceable) shall be construed so as to give effect to the intent manifested by the
provision held invalid, illegal, or unenforceable.

 

    	 

     

    

 

ARTICLE
XVI

Miscellaneous

 

Section
16.1. Non-Exclusivity of Rights. The rights of Indemnitee under this Agreement are not exclusive of any other rights
to which Indemnitee may at any time be entitled under the law, the Articles of Incorporation, the Bylaws, or any agreement. The
indemnification and advancement of Expenses for Indemnitee who has ceased to be a director, officer, employee, or agent shall
continue in full force and effect and shall inure to the benefit of the heirs, executors, and administrators of Indemnitee. The
rights of Indemnitee under this Agreement shall be contract rights. No amendment, alteration, or repeal of this Agreement can
limit or restrict any right of Indemnitee under this Agreement with respect to any action taken before the amendment, alteration,
or repeal. If a change in applicable law permits greater indemnification than that which would be afforded under this Agreement,
it is the intent of the Corporation that Indemnitee shall enjoy by this Section 16.1 the greater benefits so afforded.

 

Section
16.2. Acknowledgment of Certain Matters. Both the Corporation and Indemnitee acknowledge that, in certain instances,
applicable law or public policy may prohibit indemnification of Indemnitee by the Corporation under this Agreement or otherwise.
Indemnitee understands and acknowledges that the Corporation has undertaken or may be required in the future to undertake, by
the Securities and Exchange Commission, to submit the question of indemnification to a court in certain circumstances for a determination
of the Corporation’s right under public policy to indemnify Indemnitee.

 

Section
16.3. Waivers. The observance of any term of this Agreement may be waived (either generally or in a particular instance
and either retroactively or prospectively) by the party entitled to enforce such term only by a writing signed by the party against
which such waiver is to be asserted. Unless otherwise expressly provided herein, no delay on the part of any party hereto in exercising
any right, power, or privilege hereunder shall operate as a waiver thereof, nor shall any waiver on the part of any party hereto
of any right, power, or privilege hereunder operate as a waiver of any other right, power, or privilege hereunder nor shall any
single or partial exercise of any right, power, or privilege hereunder preclude any other or further exercise thereof or the exercise
of any other right, power, or privilege hereunder.

 

Section
16.4. Entire Agreement. This Agreement and the documents referred to herein constitute the entire agreement between
the parties hereto with respect to the matters covered hereby, and any other prior or contemporaneous oral or written understandings
or agreements with respect to the matters covered hereby are superseded by this Agreement.

 

Section
16.5. Certain Rights. The right to be indemnified or to the advancement or reimbursement of Expenses (i) is intended
to be retroactive and shall be available as to events occurring prior to the date of this Agreement and (ii) shall continue after
any rescission or restrictive modification of such provisions as to events occurring prior thereto. Nothing in this Agreement,
expressed or implied, is intended to confer any rights or remedies under or by reason of this Agreement on any person other than
the parties to this Agreement and their respective heirs, personal representatives, successors, and assigns.

 

    	 

     

    

 

Section
16.6. Governing Law. This Agreement shall be construed in accordance with and governed by the laws of the State
of Nevada without regard to any principles of conflict of laws that, if applied, might permit or require the application of the
laws of a different jurisdiction.

 

Section
16.7. Headings. The Article and Section headings in and referred to in this Agreement are for convenience of
reference only, and shall not be deemed to alter or affect the meaning or interpretation of any provisions hereof.

 

Section
16.8. Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed to be an original
and all of which together shall be deemed to be one and the same instrument.

 

Section
16.9. Use of Certain Terms. As used in this Agreement, the words “herein,” “hereof,” and “hereunder”
and other words of similar import refer to this Agreement as a whole and not to any particular paragraph, subparagraph, section,
subsection, or other subdivision. Whenever the context may require, any pronoun used in this Agreement shall include the corresponding
masculine, feminine, or neuter forms, and the singular form of nouns, pronouns, and verbs shall include the plural and vice versa.

 

[signatures
appear on following page]

 

    	 

     

    

 

IN
WITNESS WHEREOF, this Agreement has been duly executed and delivered to be effective as of the date first above written.

 

	VERB
    TECHNOLOGY COMPANY, INC.	 
	 	 
	By:	           	 
	Name:	 	 
	Title:	 	 

 

	 	 	INDEMNITEE
	 	 	 	 	Name:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]